209.39
-5.35 (-2.49%)
Previous Close | 214.74 |
Open | 220.45 |
Volume | 1,110,886 |
Avg. Volume (3M) | 1,228,516 |
Market Cap | 34,066,915,328 |
Price / Earnings (TTM) | 48.58 |
Price / Earnings (Forward) | 32.36 |
Price / Sales | 14.23 |
Price / Book | 6.60 |
52 Weeks Range | |
Earnings Date | 28 May 2025 - 2 Jun 2025 |
Profit Margin | 26.00% |
Operating Margin (TTM) | 26.14% |
Diluted EPS (TTM) | 4.33 |
Quarterly Revenue Growth (YOY) | 14.30% |
Quarterly Earnings Growth (YOY) | 32.70% |
Total Debt/Equity (MRQ) | 1.30% |
Current Ratio (MRQ) | 4.51 |
Operating Cash Flow (TTM) | 1.09 B |
Levered Free Cash Flow (TTM) | 942.78 M |
Return on Assets (TTM) | 6.57% |
Return on Equity (TTM) | 13.63% |
Market Trend
Short Term | Medium Term | ||
Industry | Health Information Services (US) | Bearish | Mixed |
Health Information Services (Global) | Bearish | Mixed | |
Stock | Veeva Systems Inc. | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | 1.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 2.0 |
Average | 1.75 |
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company’s best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company. |
|
Sector | Healthcare |
Industry | Health Information Services |
Investment Style | Mid Growth |
% Held by Insiders | 8.90% |
% Held by Institutions | 84.42% |
52 Weeks Range | ||
Price Target Range | ||
High | 285.00 (Baird, 36.11%) | Buy |
Median | 250.00 (19.39%) | |
Low | 201.00 (Morgan Stanley, -4.01%) | Sell |
Average | 250.22 (19.50%) | |
Total | 5 Buy, 3 Hold, 1 Sell | |
Avg. Price @ Call | 232.65 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Piper Sandler | 23 Apr 2025 | 255.00 (21.78%) | Buy | 220.53 |
Keybanc | 16 Apr 2025 | 250.00 (19.39%) | Buy | 220.66 |
JP Morgan | 20 Mar 2025 | 249.00 (18.92%) | Hold | 235.85 |
Baird | 06 Mar 2025 | 285.00 (36.11%) | Buy | 236.14 |
Morgan Stanley | 06 Mar 2025 | 201.00 (-4.01%) | Sell | 236.14 |
Needham | 06 Mar 2025 | 270.00 (28.95%) | Buy | 236.14 |
Scotiabank | 06 Mar 2025 | 245.00 (17.01%) | Hold | 236.14 |
Stephens & Co. | 06 Mar 2025 | 280.00 (33.72%) | Buy | 236.14 |
Truist Securities | 06 Mar 2025 | 217.00 (3.63%) | Hold | 236.14 |
No data within this time range.
Date | Type | Details |
---|---|---|
06 May 2025 | Announcement | Life Sciences Leaders Advance Unified Engagement at Veeva Commercial Summit |
29 Apr 2025 | Announcement | Announcing Veeva AI |
01 Apr 2025 | Announcement | Veeva Announces Research Site Clinical Trial Management System |
19 Mar 2025 | Announcement | Indero Marks 40th Study Live with Veeva RTSM |
11 Mar 2025 | Announcement | Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform' |
05 Mar 2025 | Announcement | Veeva Announces Fourth Quarter and Fiscal Year 2025 Results |
04 Mar 2025 | Announcement | Veeva Commercial Pulse Improves Segmentation and Targeting with Brick-Level HCP Access Data for 21 Countries |
03 Mar 2025 | Announcement | Top Global Biopharmas Standardize on Veeva China CRM Suite |
27 Feb 2025 | Announcement | Veeva Direct Data API Now Included with Vault Platform to Enable AI Innovation |
12 Feb 2025 | Announcement | Veeva to Release Fiscal 2025 Fourth Quarter and Full Year Results on March 5, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |